06:41 AM EDT, 08/12/2025 (MT Newswires) -- Eli Lilly ( LLY ) , Pfizer ( PFE ) , Novo Nordisk ( NVO ) , and Biogen (BIIB) are among a number of Western pharmaceutical companies that have applied for their drugs and treatments to be included in China's new catalog of commercial health insurance, Bloomberg reported Tuesday.

The list includes Alzheimer's therapies from Eli Lilly ( LLY ), cancer treatments from Bristol-Myers Squibb ( BMY ) , and an oral diabetes drug from Novo Nordisk ( NVO ). Other companies that featured in the list included Gilead Sciences ( GILD ) , Johnson & Johnson ( JNJ ) , and AstraZeneca ( AZN ) , the report said.

A total of 121 drugs passed the preliminary evaluation, and a final decision is expected by October or November, the report added.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)